Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Thrombotic Thrombocytopenic Purpura (TTP) is a rare blood disorder characterized by clotting in small blood vessels of the body (thromboses), resulting in a low platelet count. Symptoms include bleeding into the skin or mucus membranes, confusion, fever, headache, heart rate, shortness of breath, speech changes, weakness, and yellowish color to the skin (jaundice).

The TTP pipeline drugs market research report outlays comprehensive information on the TTP targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type, that are being developed by companies/universities. It also reviews key players involved in TTP targeted therapeutics development with respective active and dormant or discontinued projects.

TTP Pipeline Drugs Market Segmentation by Targets

Some of the primary targets in the Thrombotic Thrombocytopenic Purpura pipeline drugs market are A Disintegrin and Metalloproteinase With Thrombospondin Motifs 13, Von Willebrand Factor, and Plasminogen.

TTP Pipeline Drugs Market Analysis, by Targets

TTP Pipeline Drugs Market Analysis, by Targets

To know more about the targets in the TTP pipeline drugs market, download a free report sample

TTP Pipeline Drugs Market Segmentation by Mechanisms of Action

The primary mechanisms of action in the Thrombotic Thrombocytopenic Purpura pipeline drugs market are Von Willebrand Factor Inhibitor, A Disintegrin And Metalloproteinase With Thrombospondin Motifs 13 Activator, A Disintegrin And Metalloproteinase With Thrombospondin Motifs 13 Replacement, and Plasminogen Activator.

TTP Pipeline Drugs Market Analysis, by Mechanisms of Action

TTP Pipeline Drugs Market Analysis, by Mechanisms of Action

To know more about the MoA in the TTP pipeline drugs market, download a free report sample

TTP Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Thrombotic Thrombocytopenic Purpura pipeline drugs market are Intravenous and Subcutaneous.

TTP Pipeline Drugs Market Analysis, by Routes of Administration

TTP Pipeline Drugs Market Analysis, by Routes of Administration

To know more about the RoA in the TTP pipeline drugs market, download a free report sample

TTP Pipeline Drugs Market Segmentation by Molecule Type

The key molecule types in the TTP pipeline drugs market are Recombinant Enzyme, Aptamer, Fusion Protein, Gene Therapy, Gene-Modified Cell Therapy, Monoclonal Antibody, and Recombinant Protein.

TTP Pipeline Drugs Market Analysis, by Molecule Type

TTP Pipeline Drugs Market Analysis, by Molecule Type

To know more about the molecule type in the TTP pipeline drugs market, download a free report sample

Competitive Landscape

Some of the leading companies in the TTP pipeline drugs market are GC Biopharma Corp, KM Biologics Co Ltd, PlateletBio, Sanofi, TagCyx Biotechnologies, Takeda Pharmaceutical Co Ltd, and TargED Biopharmaceuticals BV.

TTP Pipeline Drugs Market Analysis, by Leading Companies

TTP Pipeline Drugs Market Analysis, by Leading Companies

To know more about the leading companies in the TTP pipeline drugs market, download a free report sample

TTP Pipeline Drugs Market Report Overview

Key Targets A Disintegrin and Metalloproteinase With Thrombospondin Motifs 13, Von Willebrand Factor, and Plasminogen
Key Mechanisms of Action Von Willebrand Factor Inhibitor, A Disintegrin And Metalloproteinase With Thrombospondin Motifs 13 Activator, A Disintegrin And Metalloproteinase With Thrombospondin Motifs 13 Replacement, and Plasminogen Activator
Key Routes of Administration Intravenous and Subcutaneous
Key Molecule Types Recombinant Enzyme, Aptamer, Fusion Protein, Gene Therapy, Gene-Modified Cell Therapy, Monoclonal Antibody, and Recombinant Protein
Key Companies GC Biopharma Corp, KM Biologics Co Ltd, PlateletBio, Sanofi, TagCyx Biotechnologies, Takeda Pharmaceutical Co Ltd, and TargED Biopharmaceuticals BV

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

GC Biopharma Corp
KM Biologics Co Ltd
PlateletBio
Sanofi
TagCyx Biotechnologies
Takeda Pharmaceutical Co Ltd
TargED Biopharmaceuticals BV

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Overview

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Companies Involved in Therapeutics Development

GC Biopharma Corp

KM Biologics Co Ltd

PlateletBio

Sanofi

TagCyx Biotechnologies

Takeda Pharmaceutical Co Ltd

TargED Biopharmaceuticals BV

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Drug Profiles

caplacizumab – Drug Profile

Product Description

Mechanism Of Action

History of Events

cinaxadamtase alfa – Drug Profile

Product Description

Mechanism Of Action

History of Events

GC-1126A – Drug Profile

Product Description

Mechanism Of Action

Gene Therapy for Thrombotic Thrombocytopenic Purpura – Drug Profile

Product Description

Mechanism Of Action

Gene Therapy to Activate ADAMTS13 for Thrombotic Thrombocytopenic Purpura – Drug Profile

Product Description

Mechanism Of Action

History of Events

Microlyse – Drug Profile

Product Description

Mechanism Of Action

Recombinant ADAMTS-13 Replacement for Thrombotic Thrombocytopenic Purpura – Drug Profile

Product Description

Mechanism Of Action

TAGX-0004 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Dormant Projects

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Discontinued Products

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Product Development Milestones

Featured News & Press Releases

Feb 14, 2022: Sanofi files NDA for rare blood disease drug in Japan

Jul 02, 2021: Sanofi to present on Cablivi at ISTH 2021

Nov 12, 2020: NICE recommends innovative treatment for severe blood disorder for NHS use

Apr 30, 2020: CHMP adopts positive opinion for treatment of acquired thrombotic thrombocytopenic purpura with caplacizumab

Mar 02, 2020: Cablivi (caplacizumab) approved by Health Canada for adults living with acquired thrombotic thrombocytopenic purpura (aTTP)

Dec 17, 2019: Sanofi wins prestigious drug discovery award for innovative Rare Blood Clotting Disorder treatment

Nov 06, 2019: New data on Cablivi to be presented at ASH 2019 highlight Sanofi’s commitment to treat challenging blood cancers and rare blood disorders

Mar 21, 2019: Biologics by McKesson expands specialty pharmacy capabilities to serve patients with rare and complex conditions

Feb 07, 2019: FDA approves Sanofi’s Cablivi as first therapy for rare blood disorder

Jan 09, 2019: New England Journal of Medicine publishes positive results of the pivotal trial of Cablivi (caplacizumab) for rare blood clotting disorder

Oct 30, 2018: Pharm-Olam conducts pivotal orphan disease trial, leads to first therapeutic approved for the treatment for acquired thrombotic thrombocytopenic purpura

Sep 21, 2018: A Trojan Horse delivery of possible treatment for a rare, potentially deadly, blood-clotting disorder

Sep 03, 2018: Sanofi’s Cablivi receives EC approval to treat rare blood disorder

Jun 29, 2018: Sanofi: CHMP recommends approval of Cablivi (caplacizumab)

Dec 21, 2017: Ablynx Announces Positive Data From Its Japanese Ethno-Bridging Study Of Caplacizumab

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Pipeline by GC Biopharma Corp, 2022

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Pipeline by KM Biologics Co Ltd, 2022

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Pipeline by PlateletBio, 2022

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Pipeline by Sanofi, 2022

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Pipeline by TagCyx Biotechnologies, 2022

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Pipeline by Takeda Pharmaceutical Co Ltd, 2022

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Pipeline by TargED Biopharmaceuticals BV, 2022

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Dormant Projects, 2022

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease), 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.